References for Studies in Meta-analyses: Treating Tobacco Use and Dependence: 2008 Update (continued)

References for Studies in Meta-analyses (continued)

Table 6.28. Meta-analysis (2008): Effectiveness and abstinence rates of medications relative to the nicotine patch (n = 86 studies)

Abelin T, Buehler A, Muller P, et al. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989;1:7-10.

Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002;288:468-74.

Ahluwalia JS, Okuyemi K, Nollen N, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design. Addiction 2006;101:883-91.

Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med 1998;13:1-8.

Ahmadi J, Ashkani H, Ahmadi M, et al. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J Subst Abuse Treat 2003;24:251-5.

Areechon W, Punnotok J. Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand. Clin Ther 1988;10:183-6.

Aubin HJ, Lebargy F, Berlin I, et al. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 2004;99:1206-18.

Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. Br Med J 1999;318:285-8.

Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000;160:3128-34.

Cinciripini PM, Tsoh JY, Wetter DW, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol 2005;13:282-92.

Collins BN, Wileyto EP, Patterson F, et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 2004;6:27-37.

Cooper TV, Klesges RC, Debon MW, et al. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addict Behav 2005;30:61-75.

Covey LS, Glassman AH, Stetner F, et al. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 2002;159:1731-7.

Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003;5:181-7.

da Costa CL, Younes RN, Lourenco MT. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 2002;122:403-8.

Dalsgareth OJ, Hansen NC, Soes-Petersen U, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 2004;6:55-61.

Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska primary practice smoking cessation trial group. Arch Fam Med 1998;7:425-30.

Davidson M, Epstein M, Burt R, et al. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med 1998;7:569-74.

Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 2005;25:218-25.

Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403.

Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. Practitioner 1982;226:148-151.

*Fiore MC, Kenford SL, Jorenby DE, et al. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994;105:524-33.

Fortmann SP, Killen JD, Telch MJ, et al. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford stop smoking project. JAMA 1988;260:1575-80.

George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61.

Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993;54:670-9.

Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988;259:2863-6.

Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.

Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001;69:438-44.

Gourlay SG, Forbes A, Marriner T, et al. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. Br Med J 1995;311:363-6.

Haggstram FM, Chatkin JM, Sussenbach-Vaz E, et al. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm Pharmacol Ther 2006;19:205-9.

Hall SM, Humfleet GL, Reus VI, et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004;161:2100-7.

Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002;59:930-6.

Hall SM, Munoz RF, Reus VI, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 1996;64:1003-9.

Hall SM, Tunstall CD, Ginsberg D, et al. Nicotine gum and behavioral treatment: a placebo controlled trial. J Consult Clin Psychol 1987;55:603-5.

Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health 1999;89:1701-7.

Herrera N, Franco R, Herrera L, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 1995;108:447-51.

Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1994;154:2567-72.

Hjalmarson A, Nilsson F, Sjostrom L, et al. The nicotine inhaler in smoking cessation. Arch Intern Med 1997;157:1721-8.

Holt S, Timu-Parata C, Ryder-Lewis S, et al. Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax 2005;60:120-3.

Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1999;1:169-74.

Hughes JR, Novy P, Hatsukami DK, et al. Efficacy of nicotine patch in smokers with a history of alcoholism. Alcohol Clin Exp Res 2003;27:946-54.

Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994;271:595-600.

Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.

Jensen EJ, Schmidt E, Pedersen B, et al. The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence. Int J Addict 1991;26:1223-31.

Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.

Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.

Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.

Killen JD, Fortmann SP, Davis L, et al. Nicotine patch and self-help video for cigarette smoking cessation. J Consult Clin Psychol 1997;65:663-72.

Killen JD, Fortmann SP, Murphy Jr GM, et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol 2006;74:286-94.

Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990;58:85-92.

Killen JD, Fortmann SP, Schatzberg AF, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 2000;68:883-9.

Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995;24:41-7.

Leischow SJ, Nilsson F, Franzon M, et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996;20(5):364-71.

Lewis SF, Piasecki TM, Fiore MC, et al. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med 1998;27:296-303.

Myles PS, Leslie K, Angliss M, et al. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. Anaesthesia 2004;59:1053-8.

Niaura R, Spring B, Borrelli B, et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002;70:887-96.

Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8.

Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-7.

Perng RP, Hsieh WC, Chen YM, et al. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc 1998;97:547-51.

Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004;164:2229-33.

Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation—a clinical trial in North Karelia. Tob Control 1995;4:231-5.

Richmond RL, Kehoe L, de Almeida Neto AC. Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: one year outcome. Addiction 1997;92:27-31.

Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993;153:1881-90.

*Schneider NG, Jarvik ME, Forsythe AB, et al. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav 1983; 8:253-61.

Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995;90:1671-82.

Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 1996;91:1293-306.

Simon JA, Duncan C, Carmody TP, et al. Bupropion for smoking cessation: a randomized trial. Arch Intern Med 2004;164:1797-803.

*Sonderskov J, Olsen J, Sabroe S, et al. Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark. Am J Epidemiol 1997;145:309-18.

Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995;90:31-42.

Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992;340:324-9.

Swanson NA, Burroughs CC, Long MA, et al. Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release bupropion, or both. Mil Med 2003;168:830-4.

Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5.

Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J 2000;16:717-22.

Tonnesen P, Norregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993;269:1268-71.

Tonnesen P, Norregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991;325:311-5.

Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Respir J 1999;13:238-46.

Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003;254:184-92.

Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003;24:946-55.

Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 1991;266:3133-8.

Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005;165:2286-92.

Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch Intern Med 1993;153:1917-23.

Wong GY, Wolter TD, Croghan GA, et al. A randomized trial of naltrexone for smoking cessation. Addiction 1999;94:1227-37.

Zellweger JP, Boelcskei PL, Carrozzi L, et al. Bupropion SR vs placebo for smoking cessation in health care professionals. Am J Health Behav 2005;29:240-9.

References for Studies in Meta-analyses (continued)

Table 6.28. Meta-analysis (2008): Effectiveness and abstinence rates of medications relative to the nicotine patch (n = 86 studies)

Table 6.29. Meta-analysis (2008): Effectiveness and abstinence rates for smokers not willing to quit (but willing to change their smoking patterns or reduce their smoking) after receiving nicotine replacement therapy compared to placebo (n = 5 studies)

Table 6.30. Meta-analysis (2000): Effectiveness and estimated abstinence rates for over-the-counter nicotine patch therapy (n = 3 studies)

Table 6.31. Meta-analysis (2008): Effectiveness and estimated abstinence rates for clinician training (n = 2 studies)

Table 6.32. Meta-analysis (2008): Effectiveness of clinician training on rates of providing treatment ("Assist") (n = 2 studies)

Table 6.33. Meta-analysis (2008): Effectiveness of clinician training combined with charting on asking about smoking status ("Ask") (n = 3 studies)

Table 6.34. Meta-analysis (2008): Effectiveness of training combined with charting on setting a quit date ("Assist") (n = 2 studies)

Table 6.35. Meta-analysis (2008): Effectiveness of training combined with charting on providing materials ("Assist") (n = 2 studies)

Table 6.36. Meta-analysis (2008): Effectiveness of training combined with charting on arranging for followup ("Arrange") (n = 2 studies)

Table 6.37. Meta-analysis (2008): Estimated rates of intervention for individuals who received tobacco use interventions as a covered health insurance benefit (n = 3 studies)

Table 6.38. Meta-analysis (2008): Estimated rates of quit attempts for individuals who received tobacco use interventions as a covered health insurance benefit (n = 3 studies)

Table 6.39. Meta-analysis (2008): Estimated abstinence rates for individuals who received tobacco use interventions as a covered benefit (n = 3 studies)

Table 7.1. Evidence of effectiveness of tobacco dependence interventions in specific populations. Section 4, Low SES/limited formal education (n = 5 studies)

Table 7.1. Evidence of effectiveness of tobacco dependence interventions in specific populations. Section 7, Psychiatric disorders including substance use disorders. (n = 4 studies)

Table 7.4. Meta-analysis (2008): Effectiveness of and estimated abstinence rates for counseling interventions with adolescent smokers (n = 7 studies)

Table 7.5. Meta-analysis (2008): Effectiveness of and estimated pre-parturition abstinence rates for psychosocial interventions with pregnant smokers (n = 8 studies)

Table 7.8. Meta-analysis (2008): Effectiveness of and estimated pre-parturition abstinence rates for self-help interventions with pregnant smokers (n = 2 studies)